1 of 1
Story summary
- U.S. President Donald Trump pushed a most-favoured-nation drug-pricing policy that ties U.S. prices to lower-priced countries.
- A Lancet modelling study of 195 patented medicines, representing $87.9 billion US spending, found three-quarters would lose foreign sales.
- Researchers warned firms might delay launches in reference markets, risking longer waits for European patients.
- EU drug launches fell about 35% in the ten months after Trump’s executive order, Reuters reported.